Gallium-68 Radiotracers

Gallium-68 radiotracers are particularly useful for diagnosing and monitoring cancer, as they can detect the presence and location of tumours in the body. Gallium-68 is produced through the decay of germanium-68, which has a half-life of 270 days. The production of gallium-68 radiotracers involves using a generator system, which consists of a column containing a resin loaded with germanium-68.

As the germanium-68 decays, it produces gallium-68, which is then eluted from the column using a solution of hydrochloric acid. Once the gallium-68 has been produced, it can be attached to a targeting molecule designed to bind to specific receptors or proteins in the body. This targeting molecule is often a peptide, antibody, or small molecule, and it can be labelled with gallium-68 using various methods, such as chelation or conjugation. One of the most common applications of gallium-68 radiotracers is imaging neuroendocrine tumours.

These tumours are difficult to detect using traditional imaging techniques, but they express specific receptors that can be targeted using radiotracers labelled with gallium-68. By administering a gallium-68 radiotracer and performing a positron emission tomography (PET) scan, doctors can detect the presence and location of these tumours with high accuracy. Gallium-68 radiotracers can also be used to monitor the effectiveness of cancer treatments.

For example, if a patient is undergoing chemotherapy or radiation therapy, a gallium-68 radiotracer can be used to monitor the response of the tumour to the treatment. If the tumour responds well, the radiotracer uptake will decrease over time, indicating that the treatment works. However, if the tumour is not responding, the radiotracer uptake will remain high, meaning alternative therapies may be necessary.

You are here:
home » gallium-68 radiotracers

editorial review
Editorial Review

Advancing Cancer Diagnostics: Evaluating the Potential of Ga-68 FAPi-46 PET Imaging in Solid Tumours

The study “Correlation of 68Ga-FAPi-46 PET Biodistribution with FAP Expression by Immunohistochemistry in Patients with Solid Cancers: Interim Analysis of […]

Advancing Cancer Diagnostics: Evaluating the Potential of Ga-68 FAPi-46 PET Imaging in Solid Tumours Read Post »

Scroll to Top